open access

Vol 58, No 1 (2020)
Original paper
Published online: 2020-03-16
Submitted: 2019-10-26
Accepted: 2020-02-21
Get Citation

Expression of CD163 and HLA-DR molecules on the monocytes in chronic lymphocytic leukemia patients

Wioleta Kowalska
DOI: 10.5603/FHC.a2020.0002
·
Pubmed: 32176313
·
Folia Histochem Cytobiol 2020;58(1):17-24.

open access

Vol 58, No 1 (2020)
ORIGINAL PAPERS
Published online: 2020-03-16
Submitted: 2019-10-26
Accepted: 2020-02-21

Abstract

Introduction. Human peripheral blood monocytes are the part of the leukemia microenvironment. We examined three monocyte subgroups: classical (CD14++CD16–), intermediate (CD14++CD16+) and non-classical (CD14+CD16++) monocytes. As these subpopulations can be also characterized by different levels of HLA-DR and CD163, we evaluated their expression on monocyte subpopulations of patients with chronic lymphocytic leukemia (CLL) and healthy individuals.

Material and methods. The monocyte subsets in peripheral blood of CLL patients (n = 40) and healthy controls (n = 10) were evaluated by flow cytometry. The monoclonal antibodies: anti-CD14 FITC, anti-CD16 PE-Cy5, anti-CD163 PE, anti-HLA-DR PE were used.

Results. The percentage of CD16-positive monocytes was significantly higher in CLL patients than in healthy donors. The highest percentage of CD163+ monocytes is in the ‘classical’ (CD14++CD16–) population. In turn, the non-classical monocytes constituted the majority of cells lacking HLA-DR expression. In CLL patients, there was no statistically significant relationship between the percentage of each monocyte subpopulation and the stage according to Rai Staging of CLL.

Conclusions. The presence of CD163 on classical monocytes suggests that these cells have anti-inflammatory properties. Besides, the low expression of HLA-DR on non-classical monocytes may result in impaired ability to stimulate the immune system.

Abstract

Introduction. Human peripheral blood monocytes are the part of the leukemia microenvironment. We examined three monocyte subgroups: classical (CD14++CD16–), intermediate (CD14++CD16+) and non-classical (CD14+CD16++) monocytes. As these subpopulations can be also characterized by different levels of HLA-DR and CD163, we evaluated their expression on monocyte subpopulations of patients with chronic lymphocytic leukemia (CLL) and healthy individuals.

Material and methods. The monocyte subsets in peripheral blood of CLL patients (n = 40) and healthy controls (n = 10) were evaluated by flow cytometry. The monoclonal antibodies: anti-CD14 FITC, anti-CD16 PE-Cy5, anti-CD163 PE, anti-HLA-DR PE were used.

Results. The percentage of CD16-positive monocytes was significantly higher in CLL patients than in healthy donors. The highest percentage of CD163+ monocytes is in the ‘classical’ (CD14++CD16–) population. In turn, the non-classical monocytes constituted the majority of cells lacking HLA-DR expression. In CLL patients, there was no statistically significant relationship between the percentage of each monocyte subpopulation and the stage according to Rai Staging of CLL.

Conclusions. The presence of CD163 on classical monocytes suggests that these cells have anti-inflammatory properties. Besides, the low expression of HLA-DR on non-classical monocytes may result in impaired ability to stimulate the immune system.

Get Citation

Keywords

monocyte; subpopulations; CD163; HLA-DR; chronic lymphocytic leukemia

About this article
Title

Expression of CD163 and HLA-DR molecules on the monocytes in chronic lymphocytic leukemia patients

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 58, No 1 (2020)

Article type

Original paper

Pages

17-24

Published online

2020-03-16

DOI

10.5603/FHC.a2020.0002

Pubmed

32176313

Bibliographic record

Folia Histochem Cytobiol 2020;58(1):17-24.

Keywords

monocyte
subpopulations
CD163
HLA-DR
chronic lymphocytic leukemia

Authors

Wioleta Kowalska

References (36)
  1. Caligaris-Cappio F. Inflammation, the microenvironment and chronic lymphocytic leukemia. Haematologica. 2011; 96(3): 353–355.
  2. Choi MY, Kashyap MK, Kumar D. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016; 29(1): 40–53.
  3. Ab Kadir R, Zainal Ariffin SH, Megat Abdul Wahab R, et al. Characterization of mononucleated human peripheral blood cells. ScientificWorldJournal. 2012; 2012: 843843.
  4. Ziegler-Heitbrock L. Blood Monocytes and Their Subsets: Established Features and Open Questions. Front Immunol. 2015; 6: 423.
  5. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014; 5: 514.
  6. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116(16): e74–e80.
  7. Kzhyshkowska J, Gudima A, Moganti K, et al. Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfus Med Hemother. 2016; 43(2): 66–77.
  8. Łapuć I, Eljaszewicz A, Kłoczko J, et al. Rola monocytów w patogenezie przewlekłej białaczki limfocytowej. Acta Haematologica Polonica. 2014; 45(4): 340–346.
  9. Moniuszko M, Bodzenta-Lukaszyk A, Kowal K, et al. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients. Clin Immunol. 2009; 130(3): 338–346.
  10. Gustafson MP, Abraham RS, Lin Yi, et al. Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol. 2012; 156(5): 674–676.
  11. Buechler C, Ritter M, Orsó E, et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000; 67(1): 97–103.
  12. Onofre G, Kolácková M, Jankovicová K, et al. Scavenger receptor CD163 and its biological functions. Acta Medica (Hradec Kralove). 2009; 52(2): 57–61.
  13. Moestrup SK, Møller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 2004; 36(5): 347–354.
  14. Lapuc I, Bolkun L, Eljaszewicz A, et al. Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163. Oncol Rep. 2015; 34(3): 1269–1278.
  15. Nederby L, Roug AS, Knudsen SS, et al. Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(11): 3219–3221.
  16. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017; 92(9): 946–965.
  17. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, ed.Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York: Alan R. Liss; 1987:253–264.
  18. Herishanu Y, Katz BZ, Lipsky A, et al. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am. 2013; 27(2): 173–206.
  19. Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013; 98(7): 1115–1123.
  20. Tolouei Semnani R, Moore V, Bennuru S, et al. Human monocyte subsets at homeostasis and their perturbation in numbers and function in filarial infection. Infect Immun. 2014; 82(11): 4438–4446.
  21. Abeles RD, McPhail MJ, Sowter D, et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure. Cytometry A. 2012; 81(10): 823–834.
  22. Luo Q, Xiao P, Li X, et al. Overexpression of CD64 on CD14CD16 and CD14CD16 monocytes of rheumatoid arthritis patients correlates with disease activity. Exp Ther Med. 2018; 16(3): 2703–2711.
  23. Schepers E, Houthuys E, Dhondt A, et al. Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes. PLoS One. 2015; 10(4): e0121750.
  24. Stansfield BK, Ingram DA. Clinical significance of monocyte heterogeneity. Clin Transl Med. 2015; 4: 5.
  25. Chen YCE, Mapp S, Blumenthal A, et al. The duality of macrophage function in chronic lymphocytic leukaemia. Biochim Biophys Acta Rev Cancer. 2017; 1868(1): 176–182.
  26. Galletti G, Caligaris-Cappio F, Bertilaccio MTS. B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia. Leukemia. 2016; 30(12): 2293–2301.
  27. Tsukamoto M, Seta N, Yoshimoto K, et al. CD14CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther. 2017; 19(1): 28.
  28. Mandl M, Schmitz S, Weber C, et al. Characterization of the CD14++CD16+ monocyte population in human bone marrow. PLoS One. 2014; 9(11): e112140.
  29. Yang H, Wang H, Levine YA, et al. Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight. 2016; 1(7).
  30. Liu J, Zhou Y, Huang Q, et al. CD14HLA-DR expression: A novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett. 2015; 9(3): 1167–1172.
  31. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012; 167(2): 195–205.
  32. Derlindati E, Dei Cas A, Montanini B, et al. Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation? PLoS One. 2015; 10(3): e0119751.
  33. Zarif JC, Hernandez JR, Verdone JE, et al. A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells. Biotechniques. 2016; 61(1): 33–41.
  34. Medrek C, Pontén F, Jirström K, et al. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012; 12: 306.
  35. Yuan XK, Zhao XK, Xia YC, et al. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res. 2011; 39(4): 1381–1391.
  36. Mazumdar R, Evans P, Culpin R, et al. The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. Leuk Res. 2013; 37(6): 614–618.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl